Financial Health Assessment: BRYUM CAPITAL LTD

1. Financial Health Score: B+

Explanation: Bryum Capital exhibits a robust balance sheet with substantial net assets and an exceptionally strong liquidity position, meriting a solid B+. However, the grade is tempered by a declining net asset trajectory, heavy reliance on volatile investment portfolios, and significant related-party exposures that introduce concentration risk. The company functions more as a private investment vehicle than an operating business, which changes the risk profile considerably.

2. Key Vital Signs

Heart Rate – Liquidity & Working Capital

Reading: The patient's circulatory system is functioning well. The current ratio of 11.36x means the company can cover its short-term obligations more than eleven times over – a remarkably healthy pulse. The cash position has improved from near-zero (£1,973) to £277,195, suggesting either a deliberate liquidity build or proceeds from investment realisations. This is a positive vital sign – the company is no longer operating on the edge of a cash crisis.

Blood Pressure – Leverage & Debt Health

Reading: Blood pressure is rising but remains within acceptable limits. Total leverage at 16.4% of total assets is still modest by most standards. However, the significant increase in long-term borrowing (£875,494 or +142.6%) warrants monitoring. The company has taken on substantially more debt, which could indicate either strategic leveraging of investment opportunities or a need to fund obligations. The net asset coverage of liabilities has fallen from 8.8x to 5.1x – still very comfortable, but the trajectory is concerning.

Body Mass Index – Asset Composition & Quality

Reading: The patient's body composition is heavily weighted toward investment tissue rather than operational muscle. Over 78% of total assets are in investments (fixed and current), making the company's financial health highly dependent on portfolio performance. The 2024 fair value movements tell the story: listed investments gained £3,418,666 while unlisted investments lost £2,294,974, for a net gain of £1,123,692. This volatility is the company's primary health risk.

Temperature – Profitability Trend

Reading: The patient is running a slight fever. Net assets declined by £498,700 (3.8%) in 2024, reversing the strong £1.68m gain in 2023. This volatility is characteristic of investment-driven entities where fair value movements dominate reported results. The underlying pattern over five years shows net assets oscillating between £11-13m without clear growth trajectory.

Neurological Function – Related Party & Debtors Health

Reading: There are neurological connections to group entities that represent both a strength and vulnerability. Amounts owed by group undertakings (£2.39m) represent 79% of all debtors and have increased by £156,678. This concentration means the company's financial health is partially dependent on the solvency and liquidity of related entities. The dramatic increase in trade debtors (from £58,722 to £548,501) suggests either new trading activity or delayed collections.

3. Diagnosis

Overall Condition: Stable but Under Monitoring

Bryum Capital is a privately-held investment vehicle with a substantial asset base and low leverage, but with several symptoms requiring ongoing observation:

Healthy Indicators: - Strong balance sheet foundation: Net assets of £12.4m provide a deep cushion against adversity - Excellent short-term liquidity: Current ratio above 11x leaves no doubt about ability to meet near-term obligations - Compliance health: All filings are current, no overdue documents, 20-year track record of active status - Improving cash reserves: The cash position has improved 140x year-over-year

Symptoms of Concern: - Investment portfolio volatility: The company's financial health is tied to market performance. The 2024 fair value gain of £1.12m could easily become a loss in adverse market conditions - Declining net assets: The £498,700 erosion in 2024, despite positive investment movements, suggests operational costs or other factors are consuming value - Related party dependency: £2.39m owed by group undertakings represents a concentration risk – if the group experiences distress, these receivables could become impaired - Rising leverage: The 142.6% increase in long-term debt raises questions about why additional borrowing was necessary when the company has substantial investment assets - Minimal operational infrastructure: With only one employee and negligible tangible assets, the company has limited capacity to generate revenue independently of its investment portfolio - Historical cash fragility: Prior to 2024, cash balances were consistently below £31,000, with several years below £3,000 – suggesting the company has historically operated on razor-thin cash margins

Specific Risk Assessment: Moderate

The primary risk is market and concentration risk. A sustained downturn in listed investments could rapidly erode the asset base, while the significant unlisted investment write-downs (£2.29m in 2024) demonstrate that not all portfolio bets pay off. The related party exposure means the company's "health" is partially in the hands of entities beyond its direct control.

4. Recommendations

Immediate Treatment (0-6 months)

1. Cash Management Protocol: While the improved cash position is welcome, £277,195 against £955,994 of current liabilities provides only moderate coverage. Consider maintaining a minimum cash reserve policy of 25-30% of current liabilities (£240k-£287k) – the current level barely meets this threshold.

2. Related Party Receivables Review: Commission an independent assessment of the £2.39m owed by group undertakings. Establish formal repayment schedules and monitor aging. Consider whether security or guarantees can be obtained for these balances.

3. Debt Purpose Clarification: Document and communicate the strategic rationale for the £875k increase in long-term borrowing. Ensure the cost of debt is justified by investment returns and that repayment schedules align with expected cash flows.

Medium-term Wellness Plan (6-18 months)

4. Portfolio Diversification Health Check: With over 78% of assets in investments, review portfolio concentration risk. The 2024 unlisted investment losses demonstrate the danger of illiquid positions. Consider establishing maximum position limits and regular stress-testing against market downturns.

5. Trade Debtors Monitoring: The near-10x increase in trade debtors (£58.7k to £548.5k) warrants investigation. Implement robust credit control procedures and regular aging analysis to prevent accumulation of doubtful debts.

6. Profitability Diagnosis: The declining P&L reserve despite positive fair value movements suggests underlying costs may be eroding value. Conduct a detailed review of all expenses to identify areas for efficiency improvement.

Long-term Preventive Care (18+ months)

7. Strategic Review of Capital Structure: With £1m in share capital and £11.4m in accumulated P&L reserves, consider whether the current capital structure is optimal. A partial return of capital to the shareholder could improve return on equity metrics while maintaining adequate reserves.

8. Succession and Continuity Planning: As a single-director, single-employee company, key person risk is extreme. Ensure robust documentation of investment strategies, relationships, and operational procedures to protect the £12.4m asset base.

9. Regular Financial Health Screenings: Given the volatility inherent in securities dealing, consider moving to quarterly (rather than annual) internal reviews of portfolio performance, liquidity position, and related party balances.

Vital Signs Summary Dashboard